Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key breast cancer risk factor -- Released a preliminary analysis from I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 trial of (Z)-endoxifen which met the primary endpoint with 95 percent (19/20 patients) receiving > 75 percent of planned treatment -- Announced the dosing of the first patient in a clinical trial conducted in partnership with Quantum Leap Healthcare Collaborativeä evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO) -- Received a new patent (U.

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

Generated $50.0 million in net revenue from sales of LUMRYZ™ ----2,300 patients on LUMRYZ as of September 30th, including 700 patients that